Can a Two-Drug punch knock out CMV faster in lung transplants?

NCT ID NCT07235683

Recruiting now Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding letermovir to standard antiviral treatment helps clear cytomegalovirus (CMV) infection faster in people who have received a lung transplant. About 40 participants will receive either letermovir or a placebo alongside their usual medication for 21 days. The main goal is to see if more patients achieve a negative CMV test by week three.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Letermovir (an antiviral drug) plus standard antiviral therapy (valganciclovir/ganciclovir)
What this could lead to: If successful, this combination could help lung transplant patients clear CMV infections more quickly, reducing complications and improving recovery.
What could go wrong: This is a small pilot trial with only 40 participants, so results may not apply broadly. Adding letermovir could also increase side effects or drug interactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CMV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CMV LUNG TRANSPLANT RECIPIENT

Contacts and locations

Locations

University Health Network, Toronto General Hospital
RECRUITING

Toronto, Ontario, M5G 2C4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.